key: cord-0769625-6o92v72s
authors: Ceccarelli, Giancarlo; Alessandri, Francesco; Oliva, Alessandra; Borrazzo, Cristian; Dell'Isola, Serena; Ialungo, Anna Maria; Rastrelli, Elena; Pelli, Massimiliano; Raponi, Giammarco; Turriziani, Ombretta; Ruberto, Franco; Rocco, Monica; Pugliese, Francesco; Russo, Alessandro; d'Ettorre, Gabriella; Venditti, Mario
title: The role of teicoplanin in the treatment of SARS‐CoV‐2 infection: A retrospective study in critically ill COVID‐19 patients (Tei‐COVID study)
date: 2021-03-26
journal: J Med Virol
DOI: 10.1002/jmv.26925
sha: 668d5eeef03bbb271a6b060a1b931fbb1cae34a3
doc_id: 769625
cord_uid: 6o92v72s

Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID‐19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID‐19 in critically ill patients. Fifty‐five patients with severe COVID‐19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei‐COVID group), while 21 without teicoplanin (control group). Crude in‐hospital Day‐30 mortality was lower in Tei‐COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei‐COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei‐COVID group and 57.1% of control group, without statistical difference. Serum C‐reactive protein level was significantly reduced in Tei‐COVID group compared to control group, but not other biochemical parameters. Finally, Gram‐positive were the causative pathogens for 25% of BSIs in Tei‐COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS‐CoV‐2, previously documented, is probably more effective at early clinical stages.

One of the main problems in the management of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the current unavailability of drugs specifically active in the management of coronavirus disease 2019 . 1 For this reason, the search for therapeutic resources represents the main target of research, pending the availability of an effective vaccine.

Evidence from the scientific literature highlighted that a number of glycopeptide antibiotics and their chemical derivatives have a potential antiviral activity expressed against SARS-CoV, Middle East respiratory syndrome coronavirus Ebola virus, influenza A and B viruses and feline infectious peritonitis virus. [2] [3] [4] [5] SARS-CoV-2 infection, similarly to SARS-CoV, is a multistep process including cathepsin L proteolysis of the S protein; teicoplanin was found to specifically inhibit the cathepsin L activity and to play a potential role in blocking cell entry of the cathepsin L-dependent viruses. [6] [7] [8] Based on the aforementioned, teicoplanin was suggested as an alternative complementary option to treat also SARS-CoV-2 infected patients. [9] [10] [11] Moreover, teicoplanin is a possible choice for treatment of Staphylococcus aureus superinfection, a major complication of respiratory viral infections. 12 Here we present the first retrospective analysis of a real-life cohort of critically ill patients with COVID-19 complementary treated with teicoplanin, used with a double purpose: as empiric treatment of possible S. aureus superinfection and as antiviral agent for SARS-CoV-2. Comparable severe COVID-19 cases untreated with teicoplanin were used as control group. The aim of the study was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients.

This was a multicentric, retrospective, observational research, formally named "Tei-COVID Study." The primary outcome was comparation of crude Day-30 mortality rate in two groups; the secondary outcomes were length of in-intensive care unit (ICU) stay (LOS). Other parameters evaluated were changes in (1) kidney and liver function, (2) inflammatory markers, (3) day 6-12 viral clearance rate, (4) bacterial and fungal superinfection.

We retrospectively analyzed a multicentric cohort of 55 patients with severe COVID-19 related lung involvement, progressively hospitalized in the ICUs of three teaching hospital in Lazio administrative Region (Italy), between March 9th and April 30th, 2020.

Only adult patients (>18 years) who underwent invasive mechanical ventilation due to COVID-19 related severe acute hypoxemia were included in this analysis.

Diagnosis of SARS-CoV-2 infection was defined as one positive oropharyngeal and nasopharyngeal swab performed in duplicate for SARS-CoV-2 E and S gene by a reverse transcriptase polymerase chain reaction. 13 All patients involved in the analysis were treated with ad interim best available combination therapy as suggested by the provisional guidelines published by Italian Society of Infectious and Tropical Diseases 14 : hydroxychloroquine (200 mg twice daily) plus azithromycin (500 mg daily) and tocilizumab (8 mg/kg, up to a maximum of 800 mg/ dose, twice) were administered. All patients, treated with lopinavir/ritonavir or darunavir/cobicistat, discontinued antivirals without viral clearance previously with respect to ICU admission. Steroids (dexamethasone) and unfractionated heparin were also prescribed in all patients.

Patients enrolled in one ICU received teicoplanin 6 mg/kg every 24 h (loading dose every 12 h for three doses) as a "pre-emptive" therapeutic strategy for possible S. aureus superinfection (Tei-COVID group). In other ICUs teicoplanin was not used (control group).

The source for patient data was medical records stored in the Electronic Information System of ICUs involved. The variables considered for the study included: (1) anamnestic data, (2) past clinical history (comorbidities), (3) current clinical history (including LOS and in-hospital death) and laboratory data, (4) bacterial and fungal superinfection data.

Reporting of the study conforms to broad EQUATOR guidelines. 15 Ethical approval was obtained from Ethics Committee of Policlinico Umberto I -Sapienza University of Rome, Italy (approval number/ID Prot. 109/2020).

The statistical analyses were performed with Statistical package for social science software, version 22. The data were presented as median and interquartile range ([IQR]: 25th-75th) and the presence of statistically significant differences between groups were assessed by the Mann-Whitney U test (or Student t test). The categorical variables were described as simple frequencies, proportion, or percentages (%) and then compared by the χ 2 test (or Fisher's exact test for small cells) for the two groups, since some continuous variables exhibited skewed distributions on visual inspection, and the Kolmogorov-Smirnov test indicated nonnormal distributions. Unstandardized mean difference (USMD) and their 95% CIs were analyzed between the COVID-19 and the control groups. 16, 17 USMD has been computed as the difference between the COVID-19 measured and control group, divided by the whole population variance. We have done a standard survival analysis, tracing participants from entry into the clinic to the discharge or death at 30 days. The eventfree survival in follow-up was depicted graphically by Kaplan-Meier's survivor curve, using Cox regression analysis, including the confounding factors with fixed baseline covariates. A two-sided p value test of less than .05 was considered statistically significant.

All 55 patients included in the analysis were Caucasian subjects intubated for mechanical ventilation support and admitted to the ICUs for severe respiratory complications after a median of 6 days (range: 2-10 days) from COVID-19 symptom onset. Their demographic and baseline clinical characteristics were reported in Table 1 Figure 1 ; log-rank test cut-off was greater than 0.05 at Day 14 and 30 for mortality.

Regarding the length of stay in the ICU, no statistically significant differences were observed between Tei-COVID group and control group 

Overall, 33 episodes of BSI were observed. Bacterial bloodstream superinfections were reported in 35% (12/34) of patients included in

Tei-COVID group (were due to) and in 57% (12/21) of controls as reported in Table 2 . Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. A total of two cases of candidemia were observed without statistical differences between the two groups; no cases of aspergillosis were reported.

No side effects related to teicoplanin administration were observed in Tei-COVID group.

We previously described the first report of in vivo use of teicoplanin as an antiviral agent for COVID-19. 10 Here we reported an update, 

Currently at the best of our knowledge, this is the first real-life study on the use of teicoplanin in the setting of critically ill COVID-19

patients. In our patient population, use of this drug provided no significant antiviral effect but it was associated with a promising low incidence of Gram-positive infection. This latter favorable observation, in addition to study limitations, is worthy of further study.

The authors declare that there are no conflict of interests.

Consent to publish was given by all participants and authors.

Patients signed consent to participate. 

The data that support the findings of this study are available from the corresponding author upon reasonable request. All data are available in the manuscript. Database is available writing to the corresponding author. 

Drug repurposing approach to fight COVID-19

Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Use of teicoplanin anti-Middle East respiratory syndrome coronavirus

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Teicoplanin potently blocks the cell entry of 2019-nCoV

Cathepsin L in COVID-19: from pharmacological evidence to genetics

Teicoplanin: an alternative drug for the treatment of COVID-19?

Intensive Care COVID-19 Study Group of Sapienza University. Is teicoplanin a complementary treatment option for COVID-19? The question remains

Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent

Increased mortality rates associated with Staphylococcus aureus and influenza co-infection

Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Interim guidance

Vademecum per la cura delle persone con malattia da COVID-19. Versione 2.0, 13 marzo 2020 [Handbook for the care of people with COVID-19 disease. Version 2.0-Sezione Regione Lombardia

A catalogue of reporting guidelines for health research

Statistics with confidence: confidence intervals and statistical guidelines

Univariate description and bivariate statistical inference: the first step delving into data

Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viralload

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

COVID-19: consider cytokine storm syndromes and immunosuppression

Coronavirus infections and immune responses

Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy

Bloodstream infections in critically ill patients with COVID-19

Tocilizumab for treatment of mechanically ventilated patients with COVID-19 Clin Infect Dis

The effect of antibiotics on the composition of the intestinal microbiota

Probiotics and COVID-19

Ethical approval was obtained from the Ethics Committee of Policlinico Umberto I-Sapienza University (Rome, Italy) [approval no./ID Prot. 109/2020].

http://orcid.org/0000-0001-5921-3180Massimiliano Pelli http://orcid.org/0000-0001-8148-6484Ombretta Turriziani http://orcid.org/0000-0001-6400-9168